Close Menu

NEW YORK (360Dx) – Genomica and HuaSin on Monday announced that they have entered an agreement by which HuaSin obtained exclusive rights to develop and produce a fully automated HPV genotyping assay platform that uses Genomica's technology.

Financial and other terms of the deal were not disclosed.

Guangzhou, China-based HuaSin has commenced a registration process with the China Food and Drug Administration, and subject to regulatory approval anticipates launching the platform in China in 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.